The global hemoglobinopathies market size is calculated at USD 4.87 billion in 2024, grew to USD 5.12 billion in 2025, and is predicted to hit around USD 8.08 billion by 2034, poised to grow at a CAGR of 5.2% between 2024 and 2034. The North America hemoglobinopathies market size accounted for USD 1.70 billion in 2024 and is anticipated to grow at the fastest CAGR of 5.37% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Hemoglobinopathies Market
5.1. COVID-19 Landscape: Hemoglobinopathies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Hemoglobinopathies Market, By Type
8.1. Hemoglobinopathies Market, by Type, 2024-2034
8.1.1 Thalassemia
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Sickle Cell Disease
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Hemoglobinopathies Market, By Therapy
9.1. Hemoglobinopathies Market, by Therapy, 2024-2034
9.1.1. Monoclonal Antibody Medication
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. ACE inhibitors
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Hydroxyurea
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Hemoglobinopathies Market, By Distribution Channel
10.1. Hemoglobinopathies Market, by Distribution Channel, 2024-2034
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Online Providers
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Drug Stores and Retail Pharmacy
10.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Hemoglobinopathies Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Therapy (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
Chapter 12. Company Profiles
12.1. Sangamo Therapeutics, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Global Blood Therapeutics, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. bluebird bio, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Emmaus Life Sciences Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Novartis AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Prolong Pharmaceuticals, LLC
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bioverativ Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Gamida Cell
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Celgene Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample